Investigation of 15q11-q13, 16p11.2 and 22q13 CNVs in Autism Spectrum Disorder Brazilian Individuals with and without Epilepsy

Danielle P. Moreira¹, Karina Griesi-Oliveira¹, Ana L. Bossolani-Martins², Naira C. V. Lourenço¹, Vanessa N. O. Takahashi¹, Kátia M. da Rocha¹, Eloisa S. Moreira¹, Estêvão Vadass³, Joanna Goes Castro Meira¹, Debora Bertola¹,⁴, Eoghan O’Halloran⁵, Tiago R. Magalhães⁵,⁶, Agnes C. Fett-Conte², Maria Rita Passos-Bueno¹*

¹ Centro de Pesquisas sobre o Genoma Humano e Células Tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brasil, ² Departamento de Biologia Molecular, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brasil, ³ Instituto de Psiquiatria do Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil, ⁴ Instituto da Criança da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil, ⁵ Academic Centre on Rare Diseases, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland, ⁶ National Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin, Ireland

Abstract

Copy number variations (CNVs) are an important cause of ASD and those located at 15q11-q13, 16p11.2 and 22q13 have been reported as the most frequent. These CNVs exhibit variable clinical expressivity and those at 15q11-q13 and 16p11.2 also show incomplete penetrance. In the present work, through multiplex ligation-dependent probe amplification (MLPA) analysis of 531 ethnically admixed ASD-affected Brazilian individuals, we found that the combined prevalence of the 15q11-q13, 16p11.2 and 22q13 CNVs is 2.1% (11/531). Parental origin could be determined in 8 of the affected individuals, and revealed that 4 of the CNVs represent de novo events. Based on CNV prediction analysis from genome-wide SNP arrays, the size of those CNVs ranged from 206 kb to 2.27 Mb and those at 15q11-q13 were limited to the 15q13.3 region. In addition, this analysis also revealed 6 additional CNVs in 5 out of 11 affected individuals. Finally, we observed that the combined prevalence of CNVs at 15q13.3 and 22q13 in ASD-affected individuals with epilepsy (6.4%) was higher than that in ASD-affected individuals without epilepsy (1.3%; p = 0.014). Therefore, our data show that the prevalence of CNVs at 15q13.3, 16p11.2 and 22q13 in Brazilian ASD-affected individuals is comparable to that estimated for ASD-affected individuals of pure or predominant European ancestry. Also, it suggests that the likelihood of a greater number of positive MLPA results might be found for the 15q13.3 and 22q13 regions by prioritizing ASD-affected individuals with epilepsy.

Introduction

Autism Spectrum Disorder (ASD) is a complex genetic disorder characterized by impaired social interaction and communication, and restricted, repetitive and stereotyped behavior patterns. ASD affects about 1% of the world population [1–3] and it occurs four times more commonly in males than in females [4]. In Brazil, a lower prevalence of ASD (0.27%) has been estimated, which was attributed to misdiagnosis [5]. In addition to the core symptoms, over 60% of the ASD-affected individuals can present other clinical conditions, such as epilepsy (~30%), gastrointestinal problems (9–70%), attention deficit and hyperactivity disorder – ADHD (~50%) and sleep disturbance (~50%) [6–8].

Genome-wide screenings for copy number variations (CNVs) have revealed their occurrence in 10 to 20% of ASD individuals [9–12], in which the great majority of CNVs is usually rare and private. Exceptions to this rule are CNVs at 15q11-q13, 16p11.2 and 22q13, which, combined, have been found in roughly 3 to 5% of ASD-affected individuals [10,13–15]. While most CNVs at 16p11.2 are about 600 kb [14], CNV sizes in the other two regions vary widely. The 15q11-q13 region is particularly complex, with five breakpoint clusters (BP1-BP5) that define chromosome segments more prone to genomic rearrangements. Of these, the most recurrent chromosomal abnormality among ASD-affected individuals is a 15q11-q13 duplication (between BP2 and BP3, and about 4.95 Mb) and CNVs at 15q13.2-q13.3 (between BP4 and BP5 and ranging in size from 500kb to 2 Mb) [16–19]. The size of the 22q13 CNVs ranges from 100 kb to 9 Mb and always involves SHANK3 [20,21].

CNVs at 15q11-q13, 16p11.2 and 22q13 have also been associated with other neurological conditions, such as epilepsy, schizophrenia and ADHD [22–26]. Apart from the variable clinical expressivity, these CNVs may exhibit incomplete penetrance [11,23,27]. The mechanism underlying the incomplete penetrance and the variable expressivity is not fully understood.
and it seems to depend on multiple hits [28]. Furthermore, the prevalence of these CNVs in distinct ASD subgroups (for instance, in ASD-affected individuals with epilepsy as compared to those without epilepsy) is unknown. Establishing clinical criteria to increase the likelihood of positive results for these alterations is important to prioritize genetic testing resources.

Whole-genome screening of CNVs in populations around the world have shown that their frequencies vary according to the ethnic background, allowing the distinction of populations of European, African and Asian ancestries [29,30]. Studies of CNVs at 15q11-q13, 16p11.2 and 22q13 have mostly been conducted in populations of pure or predominant European ancestry. It is not known whether they are also prevalent among ASD-affected individuals in populations of other ancestries, such as the Brazilian population, which is tri-hybrid, with important African and Amerindian contributions in addition to the European ancestry [31].

Thus, we conducted the present study to estimate the combined frequency of CNVs at 15q11-q13, 16p11.2 and 22q13 within a group of 531 Brazilian ASD-affected individuals, and we also sought to determine the frequency of CNVs in those regions by taking into account the epileptic and non-epileptic subgroups. Finally, we aimed at investigating whether the individuals with CNVs at the 15q11–13, 16p11.2 and 22q13 regions harbor additional CNVs, through a genome-wide SNP-array analysis.

Materials and Methods

Subjects

This study was approved by the Ethics Committee of the Instituto de Biociências (IB) – Universidade de São Paulo (USP). Written informed consent was obtained from all patients’ caregivers upon receiving information about the study.

Five hundred and thirty one Brazilian ASD-affected individuals were recruited for this study and ascertained at the “Centro de Pesquisa sobre o Genoma Humano e Células Tronco” (CEGH-Cel), IB-USP, following previously standardized criteria [32–34], which included a detailed anamnesis – pregnancy history, development history, age at onset, and weight, height and head circumference measurements – and a pedigree analysis. All probands were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria by psychiatrists from Instituto de Psiquiatria, Hospital das Clinicas - Universidade de Sao Paulo (IPq-USP). Whenever possible, an interview based on Autism Diagnostic Interview-Revised (ADI-R) and Childhood-Autism Rating Scale (CARS) evaluation was applied, as previously reported [32]. Epilepsy diagnosis was based on the occurrence of at least two unprovoked seizure episodes occurring more than 24 hours apart. Whenever possible, additional neurological and laboratorial tests were used to complement the diagnosis.

Blood samples from probands and parents were obtained for genomic DNA isolation, which was performed using the Autopure LS automated workstation, following manufacturer’s procedures (Gentra Systems, Minneapolis, US). All the affected boys tested negative for Fragile X Syndrome [35].

Multiplex Ligation-dependent Probe Amplification (MLPA) analysis

MLPA probe sets targeting the chromosomal regions 15q11-q13, 16p11.2 and 22q13, SALSA MLPA kits P343-B1 and P434-C1 that contain 52 probes (9 control probes, 3 covering chr22:51,115,059–51,160,754, 11 covering chr16:28,997,152–30,365,260, and 29 covering chr15:25,297,217–32,988,875). They were purchased from MRC-Holland (Amsterdam, Netherlands) and used according to the manufacturer’s protocol. The amplification products were identified and quantified by capillary electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems, Forster City, CA, US). The data were analyzed using GeneMarker software v1.95 (SoftGenetics, State College, PA, US). Threshold values for the peak height ratio were set at 0.75 and 1.3 for deletions and duplications, respectively.

Microsatellite genotyping

Seven microsatellite markers spanning the 15q11-q13 region were genotyped to identify the parental origin of the duplication of patient 2. The markers D15S1002, D15S1007 and D15S1012, ABI PRISM Linkage Mapping Set version 2.0 (Applied Biosystems, Forster City, CA, US) were genotyped following the manufacturer’s protocol. The other primer sequence pairs, D15S1043, D15S976, D15S1031 and D15S1010, were obtained from the UCSC human genome browser (http://genome.ucsc. edu/cgi-bin/hgGateway, Feb 2009 GRCh37/hg19) and a M13 tail was added to the 5’-end of each forward primer [36]. Microsatellite genotyping was performed by means of an ABI DNA Analyzer (Applied Biosystems, Forster City, CA, US). Analysis of the results was performed with the GeneMarker v1.95 software (SoftGenetics, State College, PA, US).

CNV prediction analysis from genome-wide SNP arrays

CNV prediction analysis from genome-wide SNP arrays was carried out using the Affymetrix platform (Affymetrix, Santa Clara, CA, US): GeneChip Human Mapping 100K for ASD-affected individuals 10, as described in [37], and 11, GeneChip Human Mapping 500K Array Set for families of ASD-affected individuals 2 and 3, and Genome-Wide Human SNP Array 6.0 for the remaining ASD-affected individuals and parents. Protocols were performed according to the manufacturer’s recommendations.

Data analyses were carried out with Affymetrix Genotyping Console (Affymetrix, Santa Clara, CA, US) and PennCNV (http://www.openbioinformatics.org/penncnv/), using the hg19 assembly (Genome Reference Consortium GRCh37). In both analyses we used the default parameters recommended by the manufacturers. A deletion or duplication was considered for further analyses only when detected by both methods.

We considered a CNV as potentially pathogenic according to two criteria: 1) they contained genes previously associated with ASD and/or other neuropsychiatric and neurological disorders (e.g. ADHD, global developmental delay, intellectual disability, schizophrenia and epilepsy/seizure); and/or 2) they exhibited a minimum overlap of 50% in length with CNVs previously associated with these conditions. For this, we searched Simons Foundation Autism Research Initiative (SFARI – https://gene.sfari.org/auth/Welcome.do) and Decipher (https://decipher.sanger.ac.uk/) databases. Even though we analyzed, whenever possible, if the CNVs had been inherited, we did not include this information in the classification criteria. The CNVs considered as potentially pathogenic were not found or occurred with a frequency <1% in the Database of Genomic Variants (DGV - http://dgv.tcag.ca/dgv/app/home) [38,39].

Genome-wide SNP-array data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession numbers E-MTAB-2818, E-MTAB-2819, E-MTAB-2820, E-MTAB-2821 and E-MTAB-2823.
Ancestry Analysis

We analyzed the ancestry of 9 out of 11 Brazilian ASD-affected individuals in whom high density genotyping (GeneChip Human Mapping 500K Array Set and Genome-Wide Human SNP Array 6.0) was carried out. The PLINK tool set [http://pngu.mgh.harvard.edu/purcell/plink/] [40] was used to merge the Brazilian dataset with the Human Genome Diversity Project (HGDP) [41] and HapMap project [42] datasets, and to select SNPs with a missing call inferior to 1% (geno option to 0.01), which yielded 84,805 SNPs. Next, we used Ancestry Mapper package from R, to produce AMIDs [43]. Admixture was used to produce ancestral proportions for each individual [44]. The R statistical language and environment [45] was used in most of the analysis, including the visualization, plotting data and clustering algorithms. Python was used to parse data and in some of the analysis.

Statistical Analysis

To assess the differences in CNV prevalence between the two subgroups, ASD-affected individuals without (N = 453) and with epilepsy (N = 78), we conducted two-tailed Fisher’s exact tests. P-values below 0.05 were considered statistically significant.

Results

Through MLPA analysis, we identified CNVs at 15q11-q13 between BP4 and BP5 (15q13.3), and at 16p11.2 and 22q13, respectively, in three (0.6%), five (0.9%), and three (0.6%) of the 531 (423 boys and 108 girls) Brazilian ASD-affected individuals (Table 1; clinical characteristics in Table S1), which are ethnically admixed (Table S2), with a combined prevalence of 2.1% (11/531). In four of eight of those individuals, whose parents were available for genetic testing, the CNVs were found to be de novo (affected individuals 1, 6, 10 and 11). Among the other four individuals (affected individuals 2, 3, 4, and 7), only one CNV was maternally inherited (affected individual 7) (Table 1). The parents of affected individual 2 are consanguineous and both are carriers of the CNV at 15q13.3. The parents share a haplotype at this region, suggesting a common origin of the 15q13.3 duplication. Therefore, they probably inherited the CNV from their mothers, who are sisters, while the proband inherited it from his father (Figure 1A and 1B). None of the carrier parents reported behavioral or neurological issues.

We conducted a CNV prediction analysis from genome-wide SNP arrays in the 11 ASD-affected individuals in whom we detected CNVs at 15q13.3, 16p11.2 and 22q13 regions to determine their sizes as well as to verify whether another potentially pathogenic CNV would be present. The 15q13.3, 16p11.2 and 22q13 CNVs sizes ranged from 206 kb to 2.27 Mb (Table 1). It is worth noting that the two 15q13.3 duplications were about 500 kb and included only the gene CHRNA7. Six additional CNVs (3 duplications and 3 deletions) were identified in 5 of those affected individuals (1, 2, 4, 8 and 9), two of the CNVs in individual 4 (Table 1). Four of these CNVs were inherited, while the parents of the other two affected individuals were unavailable for testing (Table 1). The 15q11.2 CNV in affected individual 2 was also present in both consanguineous parents and the maternal copy was transmitted to the affected proband (Figure 1B). Ancestry analysis was conducted in 9 out of 11 ASD-affected individuals (Table S2), which showed that they have the three main ancestral components commonly observed in the Brazilian population.

Next, we evaluated if CNVs at 15q13.3, 16p11.2 and 22q13 occurred more often among ASD-affected individuals with epilepsy. In our total sample, 78 (54 boys and 24 girls) of the 531 ASD-affected individuals had history of epilepsy (Table 2). We observed that 6 of the 453 ASD-affected individuals without epilepsy (1.3%) and 5 of the 78 ASD-affected individuals with epilepsy (6.4%) had CNVs in one of these regions. These frequencies were significantly different (p = 0.014; odds ratio = 5.1; 95% CI 1.19-20.55). CNVs at 15q13.3 and 22q13 among ASD-affected individuals with epilepsy were responsible for these differences (Table 2).

Discussion

In the Brazilian sample of ASD-affected patients, the frequencies of CNVs at 15q13.3 (0.6%), 16p11.2 (0.9%), and 22q13 (0.6%) are consistent with those described in the literature [28,38-42]. The Brazilian population is ethnically admixed, with around 56-62% of European contribution [31,46-48]. In ASD-affected individuals positive for CNVs at 15q11-q13, 16p11.2 and 22q13, we observed that the contribution of European ancestry varied from 38% to 98%. This preliminary analysis suggests that the ethnic admixture of our population is not influencing the occurrence of these CNVs.

We identified both inherited and de novo CNVs at 15q11-q13 and 16p11.2, as previously described by other groups [49-52]. Indeed, it has been established that maternally and paternally inherited CNVs at 15q11-q13 had increasing risk of ASD [28,56,57]. However, CNVs at 15q13.3, 16p11.2 and 22q13 have been associated in an increased risk of ASD [28,56,57]. In ASD-affected individuals positive for CNVs at 15q11-q13 and 16p11.2 and 22q13, we observed that the contribution of European ancestry varied from 38% to 98%. This preliminary analysis suggests that the ethnic admixture of our population is not influencing the occurrence of these CNVs.

The size of the CNVs at 16p11.2 (600kb) and 15q13.3 (500kb or 1.6Mb), are within the range of those previously reported [49,54,57], as expected due to the presence of segmental duplications that flank these regions and mediate rearrangements through non-allelic homologous recombination [49,54,63]. At 22q13 the size of the CNVs were quite variable, but always included SHANK3. Loss-of-function mutations involving SHANK3 cause Phelan-McDermid syndrome, an autosomal dominant condition with full penetrance that presents ASD among other clinical features [21,64]. In addition to the aforementioned CNVs, five ASD-affected individuals also carried at least another CNV with no correlation with the presence of CNVs at 15q13.3, 16p11.2 or 22q13. All those additional CNVs detected by the SNP-array platform overlap partially or completely CNVs previously associated with ASD or other neurological conditions [15,63-74]. Therefore, these additional CNVs, which were found in nearly 50% of our affected individuals, might contribute to the penetrance of the ASD phenotype, in accordance with the two- or multiple hit hypotheses for ASD, that is, these CNVs are not the cause ASD alone and depend on the presence of at least a second mutation [58,75]. Further studies will be necessary for testing their effect and specificity on the phenotype.

Our data suggest that CNVs at 15q13.3 and 22q13 are more prevalent among ASD-affected individuals with epilepsy than among those only with ASD. Indeed, it has been shown that 15q13.3 and 22q13 deletions represent strong genetic risk factors.
Table 1. CNVs at the chromosomal regions 15q13.3, 16p11.2 and 22q13 in the Brazilian individuals with ASD.

| Affected Individual | Region | Position (hg19) | Type  | Size (Mb) | N Genes | Inheritance | Region | Position (hg19) | Type  | Size (Mb) | Inheritance | Disease association |
|---------------------|--------|----------------|-------|-----------|----------|-------------|--------|----------------|-------|-----------|-------------|-------------------|
| 1                   | 15q13.2-q13.3 | chr15:30,941,572–32,509,926 | del   | 1.56      | 8        | de novo     | 2q13   | chr2:110,453,976–111,084,885 | dup   | 0.631      | pat         | + +               |
| 2*                  | 15q13.3 | chr15:32,024,192–32,509,926 | dup   | 0.486     | 1        | pat         | 15q11.2 | chr15:22,410,242–23,222,284 | del   | 0.812      | mat         | + +               |
| 3                   | 15q13.3 | chr15:31,956,036–32,511,581 | dup   | 0.555     | 1        | pat         | –      | –              | –     | –         | –            | – – –             |
| 4                   | 16p11.2 | chr16:29,696,973–30,191,907 | dup   | 0.495     | 25       | Pat         | 4q35.2 | chr4:186,934,286–187,137,146 | dup   | 0.203      | mat         | + +               |
| 5                   | 16p11.2 | chr16:29,517,699–30,191,895 | dup   | 0.674     | 28       | father n.a. | –      | –              | –     | –         | –            | – – –             |
| 6                   | 16p11.2 | chr16:29,613,495–30,190,030 | dup   | 0.576     | 27       | de novo     | –      | –              | –     | –         | –            | – – –             |
| 7                   | 16p11.2 | chr16:29,402,301–30,226,931 | dup   | 0.824     | 32       | Mat         | –      | –              | –     | –         | –            | – – –             |
| 8                   | 16p11.2 | chr16:29,517,699–30,191,895 | del   | 0.674     | 28       | father n.a. | 7p11.2 | chr7:57,260,919–57,882,330 | dup   | 0.621      | father n.a. | + +               |
| 9                   | 22q13.3 | chr22:51,207,581–51,234,443 | del   | 0.206     | 6        | father n.a. | 17q11.2 | chr17:25,974,257–26,075,524 | del   | 0.101      | father n.a. | – +               |
| 10*                 | 22q13.3 | chr22:50,282,986–51,304,566 | del   | 1.02      | 35       | de novo     | –      | –              | –     | –         | –            | – – –             |
| 11                  | 22q13.3 | chr22:49,033,233–51,193,680 | del   | 2.27      | 37       | de novo     | –      | –              | –     | –         | –            | – – –             |

Neurol. Dis. - Neurological Disorder; “–”- not reported in the literature; “+” reported in the literature; del – deletion; dup – duplication; n.a. – not available; pat - paternal; mat - maternal; ¥- ASD-affected individual 10 was described in [37]; * CNVs at 15q13.3 and 15q11.2 are present in both parents; doi:10.1371/journal.pone.0107705.t001
for ASD and epilepsy [76-79]. However, the contribution of 15q13.3 duplications, particularly those encompassing only CHRNA7, to both phenotypes is still uncertain [19,49,58]. Although the 15q13.3 duplication has been implicated in several psychiatric conditions [24,60,80], rare cases presented epilepsy as well [49,81,82]. Within this context, ASD-affected individual 2 deserves special attention: while his 15q13.3 duplication was paternally inherited, his parents, who do not have any history of epilepsy, probably inherited the duplication from their mothers (who are sibs). This individual also harbors a deletion at 15q11.2 (Table 1), which in turn was inherited from his mother, even though both parents carry this 15q11.2 deletion (Figure 1). De novo or inherited deletions at 15q11.2 have been associated with both epilepsy and ASD, however the relative risk that this CNV confers to ASD is low [70,83,84]. It is thus possible that CNVs both at 15q11.2 and 15q13.3 are causative factors of ASD and/or epilepsy, supporting the etiologic models that involve multiple genetic alterations in ASD, since both alterations have incomplete penetrance but have already been reported in ASD and other neuropsychiatric diseases.

None of our ASD individuals with epilepsy carry a 16p11.2 CNV. Even though CNVs at 16p11.2 have been associated with epilepsy, this finding is not unexpected, as the phenotype of patients with these CNVs is extremely variable and

Figure 1. ASD-affected individual 2 pedigree and haplotypes. A) Pedigree of the ASD-affected individual. B) Haplotype analysis of SNPs and microsatellite markers at 15q11-q13. ASD-affected individual – filled symbol; Carriers of 15q13.3 duplication and 15q11.2 deletion – symbols with a black dot in the middle; individuals unavailable or not affected – empty symbols; non-available individuals – n.a. * Distance (in kilobases) from anterior to posterior marker/dbSNP. The other microsatellite markers are not showed.

doi:10.1371/journal.pone.0107705.g001
the overlap between ASD and epilepsy is not often observed among them [55,65–68].

In summary, this work describes the combined prevalence of CNVs at 15q13.3, 16p11.2 and 22q13 as 2.1% in Brazilian ASD-affected individuals. CNVs at 15q13.3 and 22q13 were significantly more frequent in ASD-affected individuals with epilepsy in our sample; hence, these CNVs should be preferentially screened in ASD-affected individuals if resources are limited. Other potentially pathogenic CNVs were identified in 5 out of 11 ASD-affected individuals studied, thus highlighting the need for understanding how those and other genetic alterations interact to give rise to ASD and other clinical complications.

Supporting Information

Table S1 Phenotypic characteristics of ASD individuals with and without epilepsy.

| Gender | Total (N = 531) | ASD without epilepsy (N = 453) | ASD with epilepsy (N = 78) |
|--------|----------------|-------------------------------|----------------------------|
| Male   | 423            | 369                           | 54                         |
| Female | 108            | 84                            | 24                         |
| Ratio (m:f) | 4:1           | 4.4:1                         | 2:1                        |
| Mean age, years (mean ± sd) | 10.2±6.6      | 13.2±6.5                     | 9.7±6.5                    |
| CNVs at 15q13.3, 16p11.2 and 22q13 (%) | 11 (2.1) | 6 (1.3) | 5 (6.4) * |
| CNVs at 15q13.3, 22q13 (%) | 6 (1.1) | 1 (0.2) | 5 (6.4) * |

m – male; f – female; sd, standard deviation; * OR = 5.1; (p-value = 0.014).

doi:10.1371/journal.pone.0107705.t002

Table S2 Ancestral Contributions in Brazilian ASD-affected individuals.

(XLSX)

Acknowledgments

We are very grateful to the ASD-affected individuals and their family members who participated in this research. We would like to thank Cintia Ribeiro Marques for help in genetic evaluating the families, and MSc Gerson Shigeru Kobayashi for helping with manuscript revision.

Author Contributions

Conceived and designed the experiments: DM MRPB. Performed the experiments: DM ALBM NCVL KMR VNOT MRPB. Analyzed the data: DM ALBM NCVL EOH TRM KMR VNOT. Wrote the paper: DM KGO ALBM EOH TRM KMR VNOT MRPB. Contributed reagents/materials/analysis tools: EOH TRM. Evaluated the data: DM ALBM NCVL KMR VNOT. Performed the experiments: DM ALBM NCVL EOH TRM KMR VNOT. Analyzed the data: DM ALBM NCVL KMR VNOT MRPB. Contributed reagents/materials/analysis tools: EOH TRM. Evaluated the data: DM KGO ALBM EOH TRM KMR VNOT. Wrote the paper: DM KGO ALBM EOH TRM KMR VNOT.
Hyperactivity Disorder: The Role of Rare Variants and Duplications at 15q13.3
Am J Psychiatry 169: 1–10.
25. Galizia EC, Srikanta M, Palmer R, Waters J, Lench N, et al. (2012) Array comparative genomic hybridization: results from an adult population with drug-resistant epilepsy and co-morbidities. Eur J Med Genet 55: 342–348.
26. Striano P, Coppola A, Paravirdino R, Malarca M, Gisselli S, et al. (2012) Clinical significance of rare copy number variations in epilepsy: a case-controlled survey using microarray-based comparative genomic hybridization. Arch Neurol 69: 327–330.
27. Miles JH (2011) Autism spectrum disorders—a genetics review. Genet Med 13: 278–294.
28. Marshall CR, Scherer SW (2012) Genomic Structural Variants. 638: 115–135.
29. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444–454.
30. Jakobsson M, Schuel CW, Scheet P, Gibbs JR, VanLiere JM, et al. (2008) Genotype, haplotype and copy-number variation in worldwide human populations. Nature 451: 980–983.
31. Giolo SR, Soler JMP, Greenway SC, Almeida MAA, de Andrade M, et al. (2012) Brazilian urban population genetic structure reveals a high degree of admixture. Eur J Hum Genet 20: 111–116.
32. Gries-Oliveira K, Moreira DP, Davis-Wright N, Sanders S, Mason C, et al. (2012) A complex chromosomal rearrangement involving chromosomes 2, 5 and X in autism spectrum disorder. Am J Med Genet Part B, Neuropsychiatr Genet 159B: 329–336.
33. Gries-Oliveira K, Sunaga DY, Alvizi L, Vadasz E, Passos-Bueno MR (2013) An economic method for the fluorescent labeling of PCR fragments. Nat Biotechnol 18: 233–234.
34. Jehee FS, Takamori JT, Medeiros PFV, Pordeus ACB, Latini FRM, et al. (2011) The genetics of Autism Spectrum Disorders—a guide for clinicians. Curr Psychiatry Rep 15: 334.
35. Haddad L, Ingummings-Rojo L, Aso-Pena S, Aso S (1996) A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males. Hum Genet 97: 808–812.
36. Schork NJ (2000) An economic method for the fluorescent labeling of PCR fragments. Nat Biotechnol 18: 233–234.
37. Heil KM, Schaaf CP (2013) The genetics of Autism Spectrum Disorders—association scan reveals novel loci for autism. Nature 461: 802–808.
38. Kaul V, Paschall J, Church DM, Bunke B, et al. (2011) An association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 43: 822–828.
39. Qiao Y, Tyson G, Hrynchak M, Lopez-Rangel E, Hildebrand J, et al. (2013) Clinical application of 2.7M Cytogenetics array for CNV detection in subjects with idiopathic autism and/or intellectual disability. Clin Genet 83: 145–154.
40. Ku X, Roos J, Levy S, van Rensburg EJ, Gogos JA, et al. (2008) Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 40: 809–813.
41. Qiao Y, Tyson G, Hrynchak M, Lopez-Rangel E, Hildebrand J, et al. (2013) Using a combination of MLPA kits to detect chromosomal imbalances in patients with multiple congenital anomalies and mental retardation is a valuable choice for developing countries. Am J Med Genet Part B, Neuropsychiatr Genet 159B: 1581–1587.
42. Doornbos M, Sikkema-Raddatz B, Ruijvenkamp CAL, Dijkhuizen T, Bijlsma L, et al. (2012) Anterior temporal lobe seizures in patients with multiple congenital anomalies and mental retardation: a valuable choice for developing countries. Am J Psychiatry 169: 1–10.
43. Chilian B, Abdollahpour H, Bierhals T, Haltrich I, Fekete G, et al. (2013) Dysfunctions of SHANK2 and CHRNA7: benign or pathological? Hum Mutat 31: 840–850.
44. Sebat J, Sandberg K, Lander ES, Scherer SW (2004) The contribution of de novo copy number mutations to autism spectrum disorders. Cell 116: 781–795.
45.pcl 19: 1655–1664.
46. Melchior L, Bertelsen B, Debes NM, Groth C, Skov L, et al. (2013) Impact of de novo copy number variations in epilepsy: a case-control study. Epilepsia 54: 102–108.
47. Phelan K, McDermid HE (2011) The 22q11.3 Deletion Syndrome (Phelan-McDermid Syndrome). Mol Syndromol: 186–201.
48. Staal W, Daalen E, Engeland H, Hochstenbach P, et al. (2006) A population-based study of genetic variation in individuals with autism spectrum disorders. J Med Genet 43: 667–675.
49. Vorstman J, Staal W, Daalen E, Engeland H, Hochstenbach P, et al. (2006) Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism spectrum disorders. Mol Psychiatry 11: 19–25.
50. Weiss LA, Arking DE, Daly MJ, Chakravarti A (2009) A genome-wide linkage study of autism. Nat Genet 41: 802–808.
51. Versteun J, Saal W, Daalen E, Engeland H, Hochstenbach P, et al. (2006) Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism spectrum disorders. Mol Psychiatry 11: 19–25.
[Page 81] Beal JC (2013) Case Report: Neuronal Migration Disorder Associated With Chromosome 15q13.3 Duplication in a Boy With Autism and Seizures. J Child Neurol: 13–16.

[Page 82] Wiśniowiecka-Kowalnik B, Kastory-Bronowska M, Bartnik M, Derwińska K, Dymezak-Domini W, et al. (2013) Application of custom-designed oligonucleotide array CGH in 143 patients with autistic spectrum disorders. Eur J Hum Genet 21: 620–625.

[Page 83] Chaste P, Sanders SJ, Mohan KN, Klei L, Song Y, et al. (2014) Modest impact on risk for autism spectrum disorder of rare copy number variants at 15q11.2, specifically breakpoints 1 to 2. Autism Res 7: 355–362.

[Page 84] De Kovel CGF, Trucks H, Helbig I, Mefford HC, Baker C, et al. (2010) Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 133: 23–32.

[Page 85] Degenhardt F, Priebe L, Herm S, Mattheisen M, Mühleisen TW, et al. (2012) Association between copy number variants in 16p11.2 and major depressive disorder in a German case-control sample. Am J Med Genet Part B, Neuropsychiatr Genet 159B: 263–273.

[Page 86] McCarthy SE, Makarov Y, Kiroy G, Addington AM, McClellan J, et al. (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 41: 1223–1227.

[Page 87] Bedoyan JK, Kumar RA, Sudi J, Silverstein F, Ackley T, et al. (2010) Duplication 16p11.2 in a child with infantile seizure disorder. Am J Med Genet A 152A: 1567–1574.

[Page 88] Schaaf CP, Gein-Kochel RP, Nowell KP, Hunter JV, Aleck KA, et al. (2011) Expanding the clinical spectrum of the 16p11.2 chromosomal rearrangements: three patients with syringomyelia. Eur J Hum Genet 19: 152–156.